Physician profile
Benjamin J Thayer
NPI 1780979195
$2,426.15
in general payments reported to CMS, 2019-2025
26 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $102 · 2021: $318 · 2022: $309 · 2023: $293 · 2024: $390 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.45 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $213.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $192.60 | 2022-2025 | |
| Amgen INC. | $179.95 | 2019-2025 | Evenity, Prolia, Prolia |
| Supernus Pharmaceuticals, INC. | $111.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $108.27 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $97.42 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.57 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $80.87 | 2020-2022 | |
| Lilly USA, LLC | $80.39 | 2021-2024 | Jardiance, Zepbound |
| Sunovion Pharmaceuticals INC. | $49.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.14 | 2021-2022 | |
| Astellas Pharma US INC | $44.15 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $43.20 | 2021-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $42.18 | 2020-2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $41.75 | 2019 | |
| Medtronic, INC. | $34.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.44 | 2022-2024 | Xarelto |
| Abbott Laboratories | $23.83 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $20.28 | 2019 | |
| Organon LLC | $19.76 | 2025 | Nexplanon |
| Lundbeck LLC | $15.09 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $14.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.73 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.49 | 2023 | Xifaxan |
| Genentech USA, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Thayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.